Lead asset
GE07 is the current external opportunity: a PDE7 inhibitor programme available for licensing, acquisition or co-development
FOCUSED RARE DISEASE PORTFOLIO
Programme | Indication | Target | Preclinical | IND-enabling | Status |
|---|---|---|---|---|---|
GE07 | Fragile X syndrome | PDE7 | Completed | Completed | Available for partnering |
Discovery programmes | Neurodevelopmental Syndromes | Undisclosed | — | — | Internal |
